ImpediMed Takes Aim At $1.5B Market With US Launch Of L-Dex For Assessing Lymphedema In Cancer Survivors
Executive Summary
In January, ImpediMed began a national launch of L-Dex, a bioimpedance spectroscopy device designed to allow early detection and treatment of secondary lymphedema, a condition caused by cancer treatment that affects about 900,000 US patients each year – a market estimated at $1.5 billion. Early detection and treatment can greatly reduce or even reverse progression of the disease, and the company is also investigating potential applications in heart failure, a much larger market.